Epoch Biosciences   Report issue

For profit Phase 1 Phase 3
Founded: Hi Chi Minh City Vietnam (1997)
Status: No NME R&D (1997)

Organization Overview

First Clinical Trial
2013
NCT02063607
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Active Ingredients

Drugs in Phase 3 Trials (4)

docetaxel (taxotere) (2 trials)

Filgrastim (neupogen) (2 trials)

nanocovax (2 trials)

trastuzumab (herceptin) (2 trials)

Drugs in Phase 1 Trials (1)

peginterferon lambda-1a (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Hepatitis (Phase 1)

Hepatitis A (Phase 1)

Hepatitis C (Phase 1)

Hepatitis C, Chronic (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 5